文献速递瓣膜病与结构性心脏病

球囊扩张瓣与自膨胀瓣用于小号外科主动脉瓣生物瓣衰败的随机对照研究

Balloon- vs Self-Expanding Valve Systems for Failed Small Surgical Aortic Valve Bioprostheses.
PubMed 文献 · J Am Coll Cardiol · 2022-05-18

本研究将外科小号(≤23 mm)主动脉瓣生物瓣衰败患者随机分配至球囊扩张瓣(SAPIEN 3/ULTRA)或自膨胀瓣(Evolut R/PRO/PRO+)行瓣中瓣经导管主动脉瓣置换术。共102例随机,98例最终手术。30天超声显示自膨胀瓣组平均和最大跨瓣压差更低,严重瓣膜-患者不匹配有更低趋势,两组均无中重度主动脉瓣反流,30天临床结局无差异。

要点

  • 小号外科瓣衰败行ViV-TAVR,自膨胀瓣较球囊扩张瓣30天超声血流动力学更优
  • 自膨胀瓣组严重PPM有更低趋势(44% vs 64%,P=0.07)
  • 两组均无中重度主动脉瓣反流,30天无死亡或卒中事件

核心结论

  • 小号外科主动脉瓣生物瓣衰败患者行ViV-TAVR,自膨胀瓣与超声评估的瓣膜血流动力学改善相关。
  • 两组术中侵入性评估的瓣膜血流动力学及30天临床结局无差异。

研究设计与样本

  • 随机对照试验,将外科小号(≤23 mm)主动脉瓣生物瓣衰败患者随机分配至球囊扩张瓣或自膨胀瓣行ViV-TAVR。
  • 共102例随机,98例最终接受ViV-TAVR(球囊扩张瓣n=46,自膨胀瓣n=52)。
  • 主要终点为30天多普勒超声评估的瓣膜血流动力学(最大/平均残余压差、严重PPM或中重度主动脉瓣反流)。

主要发现

  • 自膨胀瓣组平均跨瓣压差低于球囊扩张瓣组(15±8 mmHg vs 23±8 mmHg,P<0.001)。
  • 自膨胀瓣组最大跨瓣压差低于球囊扩张瓣组(28±16 mmHg vs 40±13 mmHg,P<0.001)。
  • 自膨胀瓣组严重PPM有更低趋势(44% vs 64%,P=0.07)。
  • 两组均无中重度主动脉瓣反流病例。
  • 55例连续患者(自膨胀瓣n=27,球囊扩张瓣n=28)术中行侵入性瓣膜血流动力学评估,两组平均和峰值跨瓣压差无差异(P=0.41和P=0.70)。

关键数值与推荐

  • 外科瓣尺寸≤23 mm为入选标准。
  • 主要终点为30天多普勒超声评估的瓣膜血流动力学。
  • 30天临床结局两组无差异,无死亡或卒中事件。

临床怎么用

  • 对于小号外科主动脉瓣生物瓣衰败患者,选择自膨胀瓣行ViV-TAVR可能获得更优的超声血流动力学。
  • 术中侵入性血流动力学评估未显示两组差异,决策需综合超声与临床结局。

局限性

  • 样本量较小(98例接受手术)。
  • 严重PPM差异仅为趋势(P=0.07),未达统计学显著。
  • 侵入性血流动力学评估仅纳入55例连续患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) field have been obtained from retrospective studies. OBJECTIVES: The purpose of this study was to compare the hemodynamic results between the balloon-expandable valve (BEV) SAPIEN (3/ULTRA, Edwards Lifesciences) and self-expanding valve (SEV) Evolut (R/PRO/PRO+, Medtronic) in ViV-TAVR. METHODS: Patients with a failed small (≤23 mm) surgical valve were randomized to receive a BEV or an SEV. The primary endpoint was valve hemodynamics (maximal/mean residual gradients, severe prosthesis patient mismatch [PPM], or moderate-severe aortic regurgitation) at 30 days as evaluated by Doppler echocardiography. RESULTS: A total of 102 patients were randomized, and of these, 98 patients finally underwent a ViV-TAVR procedure (BEV: n = 46, SEV: n = 52). The procedure was successful in all cases, with no differences in clinical outcomes at 30 days between groups (no death or stroke events). Patients in the SEV group exhibited lower mean and maximal transvalvular gradient values (15 ± 8 mm Hg vs 23 ± 8 mm Hg; P ˂ 0.001; 28 ± 16 mm Hg vs 40 ± 13 mm Hg, P ˂ 0.001), and a tendency toward a lower rate of severe PPM (44% vs 64%; P = 0.07). There were no cases of moderate-severe aortic regurgitation. In total, 55 consecutive patients (SEV: n = 27; BEV: n = 28) underwent invasive valve hemodynamic evaluation during the procedure, with no differences in mean and peak transvalvular gradients between both groups (P = 0.41 and P = 0.70, respectively). CONCLUSIONS: In patients with small failed aortic bioprostheses, ViV-TAVR with an SEV was associated with improved valve hemodynamics as evaluated by echocardiography. There were no differences between groups in intraprocedural invasive valve hemodynamics and 30-day clinical outcomes (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprostheses. The 'LYTEN' Trial; NCT03520101).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rodés-Cabau J, Abbas AE, Serra V, et al. Balloon- vs Self-Expanding Valve Systems for Failed Small Surgical Aortic Valve Bioprostheses. J Am Coll Cardiol. 2022. PMID: 35597385. doi:10.1016/j.jacc.2022.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。